Dr. Sally Bennett Appointed to the Supervisory Board of Innate Pharma
Marseille, France – (BUSINESS WIRE) – Regulatory news:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (« innate” or the “ association “) on the results of the shareholders’ vote at the joint general assembly meeting held in Marseille on May 20, 2022. All decisions were voted on based on the recommendations of the Board of Directors.
134 votes were recorded out of a total of 32,598,725 shares giving 33,088,040 voting rights, i.e. a quorum of 40.88%.
Resolutions, resolution voting result, and documentation related to the general assembly meeting as well as the re-meeting will be available in the documentation section for the 2022 general meeting on the company’s website.
The 2021 Global Registration Document is available on the company’s website.
During this meeting, Dr. Sally Bennett was appointed as the new member of the supervisory board. She was appointed as a member of the Audit Committee during the Supervisory Board held on May 20, 2022.
« We are pleased to welcome Dr. Sally Bennett as a new member of the Innate Pharma Supervisory Board “, comments Hervey Brilly, Chair of the Innate Pharma Supervisory Board. « His expertise in finance and his in-depth understanding of the biopharma sector and capital markets will be a true asset to the company. As Innate continues to implement its strategy, we are committed to evolving the composition of the Board of Directors to ensure we have the right balance of skills and experience to advance our goals while representing all of Innate’s stakeholders. »
Dr. Sally Bennett has over 20 years of experience in financial analysis and capital markets in the life sciences and biopharmaceutical industry. She is currently a senior member of the investment team (part-time) at HealthCor, a US healthcare investment firm, where she previously managed the public biopharmaceutical investment portfolio. Today, it is involved in directing the recent development of funds towards private investment. She is a member of the Institute of Directors (IoD) and is a CertIoD certified. Dr. Bennett holds a Bachelor’s degree in Anatomical Sciences and a Doctor of Medicine with distinction from the University of Manchester.
After the meeting, Patrick Langlois announced that he was resigning from the Innate’s supervisory board.
« Patrick has been a highly valued member of the Supervisory Board and we are grateful to him for his significant contribution over the past twelve years. On behalf of the Supervisory Board, I want to thank him for his commitment throughout these years and wish him well for the future. ‘, announced Hervey Braille.
To date, the Supervisory Board of Innate Pharma consists of:
Hervé Braille, Chairman of the Supervisory Board
Irina Stats Granzer, Vice President
Posts by Bevance, represented by Olivier Martinez
About Inet Pharma:
Innate Pharma SA is a clinical-stage biotechnology company specializing in immuno-oncology dedicated to improving the treatment of cancer through innovative therapeutic antibodies that exploit the immune system.
Innate Pharma’s large antibody group includes several candidates that are likely to be early clinical and preclinical candidates in cancers where the medical need is great.
Innate Pharma is a leader in understanding the biology of natural killer cells and has advanced expertise in the tumor microenvironment and oncogene antigens, as well as antibody engineering. Its innovative approach has enabled it to build a diversified ownership portfolio and form alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S or Sanofi as well as a multi-product partnership with AstraZeneca.
Innate Pharma is headquartered in Marseille, has a subsidiary in Rockville (Maryland, United States), and is listed on Euronext Paris and Nasdaq in the United States.
Find Innate Pharma at www.innate-pharma.com.
useful information :
Euronext: IPH Nasdaq: IPHA
Disclaimer regarding forward-looking information and risk factors:
This press release contains forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain terms, including “believes,” “likely,” “expect,” “will,” and other expressions Similar is intended to identify forward-looking statements. Although the Company considers its expectations to be based on reasonable assumptions, such forward-looking statements may be subject to doubt due to a certain number of risks and uncertainties, which could lead to results materially different from those expected. These risks and uncertainties include in particular the uncertainties inherent in research and development, including those relating to safety, progress and results of clinical trials and preclinical studies ongoing or planned, reviews and authorizations by regulatory authorities regarding the Company’s product candidates, and commercial efforts, The Company’s ability to continue to raise funds for its development and the overall impact of the COVID-19 pandemic on healthcare systems and activities as well as the activities, financial condition and results of the Company. For additional considerations in terms of risks and uncertainties that could differ in actual results, financial condition, performance and successes of the Company, please refer to the “Risk Factors” section of the Global Recording Document. (AMF), available on the websites of Innate Pharma (www.innate-pharma.com) and AMF (www.amf-france.org), and public documents and reports filed with the US Securities and Exchange Commission (SEC), including That annual report on “Form 20-F” for the fiscal year ending December 31, 2021 and subsequent documents and reports submitted to the AMF or the Securities and Exchange Commission, or made public by the Company.
This press release and the information it contains do not constitute an offer to sell or subscribe or a solicitation of an order to buy or subscribe for shares of Innate Pharma in any country whatsoever.
Investors and press relations
+33 (0) 4 84 90 32 88
+33 (0) 9 81 87 46 72